

LIST OF FIGURES

Figure No.	Figure Title	Page No.
Figure 1.1	Structural formula of NISO	5
Figure 1.2	Structural formula of DE	7
Figure 2.3.1	(A) Nanoemulsion and (B) macro-emulsion with droplet diameters of <100 nm and >1 μm , respectively	29
Figure 2.3.2	Schematic representation of high pressure valve homogenizer	33
Figure 2.5.1	Site of action of new anticoagulants in the coagulation cascade	42
Figure 2.5.2	Structural formula of Dabigatran Etexilate	42
Figure 2.5.3	Structural formula of Nisoldipine	47
Figure 3.4.1	UV Absorption spectrum of DE in (A) 0.01N HCl, (B) phosphate buffer pH 6.8 (C) phosphate buffer pH 7.4 and (D) methanol	74
Figure 3.4.2	Calibration curves of DE in (A) 0.01N HCl, (B) phosphate buffer pH 6.8 (C) phosphate buffer pH 7.4 and (D) methanol	77
Figure 3.4.3	Calibration curves of DE at 0 h and 24 h time points in (A) 0.01N HCl, (B) phosphate buffer pH 6.8 (C) phosphate buffer pH 6.8 and (D) methanol for stability [y_1 , R_1 = initial, y_2 , R_2 = at 24h]	80
Figure 3.4.4	Specificity study graph between DE and excipients in (A) 0.01N HCl, (B) phosphate buffer pH 6.8, (C) phosphate buffer pH 7.4 (D) methanol	86
Figure 3.4.5	Chromatogram of DE solution by HPLC at 230nm	89
Figure 3.4.6	Calibration curve of DE by HPLC at 230 nm	90
Figure 3.4.7	Calibration curves of DE at 0 h and 24 h time points for Stability by HPLC at 230 nm [y_1 , R_1 = initial, y_2 , R_2 = at 24h]	92
Figure 3.4.8	Chromatograph of DE in plasma by HPLC at 230nm	93
Figure 3.4.9	Calibration curve of DE in plasma by HPLC at 230 nm	94
Figure 3.4.10	Calibration curves of DE at 0 h and 24 h time points for Stability by HPLC in plasma at 230 nm [y_1 , R_1 = initial, y_2 , R_2 = at 24h]	95
Figure 3.4.11	UV Absorption Spectrum of NISO in (A) 0.1N HCl with	98

	0.5% SLS, (B) Phosphate buffer pH 6.8 with 0.5% SLS and (C) phosphate buffer pH 7.4 with 0.5% SLS and (D) methanol	
Figure 3.4.12	Calibration curves of NISO in (A) 0.1N HCl with 0.5% SLS (B) phosphate buffer pH 6.8 with 0.5% SLS, (C) phosphate buffer pH 7.4 with 0.5% SLS and (D) methanol	101
Figure 3.4.13	Calibration curves of NISO at 0 h and 24 h time points in (A) 0.1N HCl with 0.5% SLS, (B) phosphate buffer pH 6.8 with 0.5% SLS, (C) phosphate buffer pH 7.4 with 0.5% SLS and (D) methanol for stability study [y_1 , R_1 = initial, y_2 , R_2 = at 24h]	105
Figure 3.4.14	Specificity and interference study graph between NISO and excipients in (A) 0.1N HCl with 0.5% SLS, (B) phosphate buffer pH 6.8 with 0.5% SLS, (C) phosphate buffer pH 7.4 with 0.5% SLS and (D) methanol	111
Figure 3.4.15	Chromatogram of NISO solution by HPLC at 235nm	113
Figure 3.4.16	Calibration curve of NISO by HPLC	114
Figure 3.4.17	Calibration Curves of NISO at 0 h and 24 h time points for Stability by HPLC	116
Figure 3.4.18	Chromatogram of NISO in plasma by HPLC at 235nm	118
Figure 3.4.19	Calibration curve of NISO in Plasma by HPLC	118
Figure 3.4.20	Calibration Curves of NISO at 0 h and 24 h time points for Stability in plasma by HPLC [y_1 , R_1 = initial, y_2 , R_2 = at 24h]	120
Figure 4.6.1	UV spectrum of DE in 0.01N HCl	139
Figure 4.6.2	UV spectrum of NISO in 0.1N HCl with 0.5% SLS	139
Figure 4.6.3	FTIR spectrum of DE	140
Figure 4.6.4	FTIR spectrum of NISO	140
Figure 4.6.5	DSC thermogram of DE	142
Figure 4.6.6	DSC thermogram of NISO	143
Figure 4.6.7	FTIR spectrum of placebo mix for DE SMEDDS	146
Figure 4.6.8	FTIR spectrum of DE SMEDDS	146
Figure 4.6.9	FTIR spectrum of placebo mix for NISO SMEDDS	147
Figure 4.6.10	FTIR spectra of NISO SMEDDS	147

Figure 4.7.1	Pseudo ternary phase diagrams of DE SMEDDS formulations composed of oil, S_{mix} and water.	154
Figure 4.7.2	Pseudo ternary phase diagrams of NISO SMEDDS formulations composed of oil, S_{mix} and water.	154
Figure 4.7.3	Contour plots showing effect of X_1 , X_2 , X_3 on Y_1 and Y_2 for DE SMEDDS	158
Figure 4.7.4	Response surface plot showing effect of X_1 , X_2 , X_3 on Y_1 and Y_2 for DE SMEDDS	158
Figure 4.7.5	Overlay plot of desirable DE SMEDDS for D-optimal design	159
Figure 4.7.6	Contour plots showing effect of independent variables on Globule size and % Transmittance for NISO SMEDDS	164
Figure 4.7.7	Response surface plots showing effect of independent variables on Globule size and % Transmittance for NISO SMEDDS	165
Figure 4.7.8	Desirability plot of optimized batch of NISO SMEDDS	167
Figure 4.8.1	Globule size of optimized batch of DE SMEDDS	170
Figure 4.8.2	Globule size of optimized batch of NISO SMEDDS	170
Figure 4.8.3	Zeta potential of optimized batch of DE SMEDDS	171
Figure 4.8.4	Zeta potential of optimized batch of NISO SMEDDS	171
Figure 4.8.5	TEM image of optimized batch of DE SMEDDS	174
Figure 4.8.6	TEM image of optimized batch of NISO SMEDDS	174
Figure 4.8.7	<i>In vitro</i> dissolution profile of DE SMEDDS and drug suspension in 0.01N HCl and pH 6.8 phosphate buffer	176
Figure 4.8.8	<i>In vitro</i> dissolution profile of NISO SMEDDS and drug suspension in 0.1N HCl +0.5% SLS and pH 6.8 phosphate buffer +0.5% SLS.	177
Figure 4.8.9	<i>In vitro</i> diffusion profile of DE SMEDDS and drug suspension in 0.01N HCl and pH 6.8 phosphate buffer	178
Figure 4.8.10	Release kinetics curves for DE SMEDDS in 0.01N HCl	178
Figure 4.8.11	Release kinetics curves for DE SMEDDS in pH 6.8 phosphate buffer	179
Figure 4.8.12	<i>In vitro</i> diffusion profile of NISO SMEDDS and drug suspension in 0.1N HCl with 0.5% SLS and pH 6.8	180

	phosphate buffer with 0.5% SLS	
Figure 4.8.13	Release kinetics curves for NISO SMEDDS in 0.1N HCl with 0.5% SLS	181
Figure 4.8.14	Release kinetics curves for NISO SMEDDS in pH 6.8 Phosphate buffer with 0.5% SLS	182
Figure 4.8.15	<i>Ex vivo</i> release study of DE SMEDDS and drug suspension in 0.01N HCl and pH 6.8 phosphate buffer	184
Figure 4.8.16	<i>Ex vivo</i> release study of NISO SMEDDS and drug suspension in 0.1N HCl with 0.5% SLS and pH 6.8 phosphate buffer with 0.5% SLS	185
Figure 5.8.1	Effect of S_{mix} system concentration for DE NE and NISO NE	199
Figure 5.10.1	Contour plots showing effect of independent variables on GS and PDI for DE NE	206
Figure 5.10.2	Response surface plots showing effect of independent variables on GS and PDI for DE NE	206
Figure 5.10.3	Desirability plot of optimized batch of DE NE	207
Figure 5.10.4	Contour plots showing effect of independent variables on GS and PDI for NISO NE	212
Figure 5.10.5	Response surface plots showing effect of independent variables on GS and PDI for NISO NE	212
Figure 5.10.6	Desirability plot for optimized batch of NISO NE	213
Figure 5.11.1	Globule size for optimized batch of DE NE	214
Figure 5.11.2	Globule size for optimized batch of NISO NE	215
Figure 5.11.3	Zeta potential of optimized batch of DE NE	216
Figure 5.11.4	Zeta potential of optimized batch of NISO NE	216
Figure 5.11.5	Transmission Electron Microscopy (TEM) image of optimized batch for DE NE	217
Figure 5.11.6	Transmission Electron Microscopy (TEM) image of optimized batch for NISO NE	218
Figure 5.11.7	FTIR spectrum of placebo mix for DE NE	221
Figure 5.11.8	FTIR spectrum of DE NE	222

Figure 5.11.9	FTIR spectrum of placebo mix for NISO NE	222
Figure 5.11.10	FTIR spectrum of NISO NE	223
Figure 5.11.11	<i>In vitro</i> dissolution profile of DE NE and drug suspension in 0.01N HCl and pH 6.8 phosphate buffer	224
Figure 5.11.12	<i>In vitro</i> dissolution profile of NISO NE and drug suspension in 0.01N HCl and pH 6.8 phosphate buffer	224
Figure 5.11.13	<i>In vitro</i> diffusion profile of DE NE and drug suspension in 0.01N HCl and pH 6.8 phosphate buffer	225
Figure 5.11.14	Release kinetics curves in 0.01N HCl for DE NE	226
Figure 5.11.15	Release kinetics curves in pH 6.8 phosphate buffer for DE NE	227
Figure 5.11.16	<i>In vitro</i> diffusion profile of NISO NE and drug suspension in 0.01N HCl and pH 6.8 phosphate buffer	228
Figure 5.11.17	Release kinetics curves in 0.1N HCl for NISO NE	229
Figure 5.11.18	Release kinetics curves in pH 6.8 phosphate buffer for NISO NE	229
Figure 5.11.19	<i>Ex vivo</i> release study of DE NE and drug suspension from rat stomach and intestine tissue.	230
Figure 5.11.20	<i>Ex vivo</i> release study of NISO NE and drug suspension from rat stomach and intestine tissue.	231
Figure 6.3.1	Bar chart depicting the percent cell viability for (A) DE-SMEDDS, DE suspension, Placebo SMEDDS, Phosphate buffer saline (PBS) and Triton-X 100 (B) DE-NE, DE suspension, Placebo NE, Phosphate buffer saline (PBS) and Triton-X 100 (C) NISO-SMEDDS, NISO suspension, Placebo SMEDDS, Phosphate buffer saline (PBS) and Triton-X 100 (D) NISO-NE, NISO suspension, Placebo NE, Phosphate buffer saline (PBS) and Triton-X 100	241
Figure 6.3.2	Cell uptake studies by FACS for coumarin-6 loaded dye solution (a, b); coumarin-6 loaded SMEDDS (a', b') and coumarin-6 loaded NE (a'', b'') at 1 h (a, a', a'') and 4 h (b, b', b'') in Caco-2 cells for DE	242

Figure 6.3.3	Cell uptake studies by FACS for coumarin-6 loaded dye solution (a, b); coumarin -6 loaded SMEDDS (a', b') and coumarin -6 loaded NE (a'', b'') at 1 h (a, a', a'') and 4 h (b, b', b'') in Caco-2 cells for NISO	243
Figure 6.3.4	Mean fluorescence intensity plot of dye solution, Coumarin-6 loaded SMEDDS and Coumarin-6 loaded NE for DE	244
Figure 6.3.5	Mean fluorescence intensity plot of dye solution, Coumarin-6 loaded SMEDDS and Coumarin-6 loaded NE for NISO	244
Figure 6.3.6	Qualitative cellular uptake of Coumarin-6 solution in Caco-2 cells; at 1 h (A–D) and 4 h (E-H); Green fluorescence spots represents dye solution, Blue fluorescence represents DAPI-stained nuclei,(C and G) represents overlapped images and (D and H) represents Differential Interference Contrast (DIC) images showing cells.	245
Figure 6.3.7	Qualitative cellular uptake of DE SMEDDS in Caco-2 cells; at 1 h (A–D) and 4 h (E-H); Green fluorescence spots represents dye-loaded SMEDDS, Blue fluorescence represents DAPI-stained nuclei,(C and G) represents overlapped images and (D and H) represents Differential Interference Contrast (DIC) images showing cells.	246
Figure 6.3.8	Qualitative cellular uptake of DE NE in Caco-2 cells; at 1 h (A–D) and 4 h (E-H); Green fluorescence spots represents dye-loaded NE, Blue fluorescence represents DAPI-stained nuclei,(C and G) represents overlapped images and (D and H) represents Differential Interference Contrast (DIC) images showing cells.	246
Figure 6.3.9	Qualitative cellular uptake of NISO SMEDDS in Caco-2 cells; at 1 h (A–D) and 4 h (E-H); Green fluorescence spots represents dye-loaded SMEDDS, Blue fluorescence represents DAPI-stained nuclei,(C and G) represents overlapped images and (D and H) represents Differential Interference Contrast (DIC) images showing cells.	247
Figure 6.3.10	Qualitative cellular uptake of NISO NE in Caco-2 cells; at 1	247

	h (A–D) and 4 h (E–H); Green fluorescence spots represents dye-loaded NE, Blue fluorescence represents DAPI-stained nuclei,(C and G) represents overlapped images and (D and H) represents Differential Interference Contrast (DIC) images showing cells.	
Figure 7.3.1	Plasma concentration profiles of orally administered DE formulations in rats	260
Figure 7.3.2	Plasma concentration profiles of orally administered NISO formulations and drug suspension in rats	263
Figure 7.3.3	Plasma concentration profiles of orally administered DE SMEDDS and DE NE formulations in animals pretreated with saline and CHM	264
Figure 7.3.4	Plasma concentration profiles of orally administered NISO SMEDDS and NISO NE formulations to pretreated groups of animals with saline and CHM	266
Figure 7.3.5	Graph showing results of pharmacodynamic study for NISO SMEDDS and NISO NE in comparison to drug suspension	268